Vivesto AB
VIVE
Rank in Stocks
#30973
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes... Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its leading human oncology product is Apealea (paclitaxel micellar), designed for the treatment of ovarian cancer. The company's pipeline for human health also includes Docetaxel micellar, a patented formulation combining the cytotoxin docetaxel with XR-17, which is currently in Phase 1b clinical trials for prostate cancer, as well as Cantrixil for addressing ovarian cancer. For animal health, Vivesto provides Paccal Vet, leveraging its XR-17 encapsulation technology to deliver paclitaxel for canine mastocytoma, and Doxophos Vet, a proprietary doxorubicin formulation used to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) until its name change to Vivesto AB in March 2022.
Share Price
$0.74479082
Last synced: 2026-11-09
Market Cap
$4.01M
Change (1 day)
5.09%
Change (1 year)
-70.21%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Vivesto AB (VIVE)
Category
Healthcare
EPS for Vivesto AB (VIVE)
EPS as of June 2026 TTM: $-0.08
According to Vivesto AB's latest financial reports, its current EPS (TTM) is $-0.08. At the end of 2025 the company had an EPS of $-0.01, equal to its 2024 EPS of $-0.01.
EPS history for Vivesto AB from 2005 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.08 | 707.00% |
| 2025 | $-0.01 | -10.45% |
| 2024 | $-0.01 | -99.68% |
| 2023 | $-2.07 | 2,816.48% |
| 2022 | $-0.07 | 107.00% |
| 2021 | $-0.03 | 1,219.23% |
| 2020 | 0.00 | -95.74% |
| 2019 | $-0.06 | 13.78% |
| 2018 | $-0.05 | -46.62% |
| 2017 | $-0.10 | -12.14% |
| 2016 | $-0.11 | 19.64% |
| 2015 | $-0.10 | -21.17% |
| 2014 | $-0.12 | 21.77% |
| 2013 | $-0.10 | -7.94% |
| 2012 | $-0.11 | -28.37% |
| 2011 | $-0.15 | 290.70% |
| 2010 | $-0.04 | 138.89% |
| 2009 | $-0.02 | 5.19% |
| 2008 | $-0.02 | -45.58% |
| 2007 | $-0.03 | 48.95% |
| 2006 | $-0.02 | -379.41% |
| 2005 | $0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | -8,156.26% |
DE
|
|
| $6.08 | -7,631.10% |
DE
|
|
| $1.55 | -2,021.44% |
JP
|
|
| $3.66 | -4,635.32% |
CH
|
|
| $0.45 | -657.62% |
IL
|
Questions about Vivesto AB's earnings per share (EPS)
What is Vivesto AB's earnings per share (EPS)?
Vivesto AB's earnings per share (EPS) over the last twelve months is $-0.08, as of Jun 2026.
What was Vivesto AB's earnings per share (EPS) in 2025?
In 2025, Vivesto AB's earnings per share (EPS) was $-0.01, compared with $-0.01 in 2024.
How has Vivesto AB's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Vivesto AB's earnings per share (EPS) was highest in 2020 (0.00) and lowest in 2023 ($-2.07).
How does Vivesto AB's earnings per share (EPS) compare with similar companies?
Vivesto AB's earnings per share (EPS) ($-0.08) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.